Axumin, a radioactive diagnostic agent for injections, recently received approval from the U.S. Food and Drug Administration (FDA), as the new technology may be useful in detecting recurrent prostate cancer.
Boehringer Ingelheim, a pharmaceutical company focused on research, recently announced that it seeks to improve the access that HIV and AIDS patients have to antiretroviral medication to treat their illnesses.
Leaders at the annual meeting of the American Academy of Neurology recently announced some important progress that has been made with regard to understanding and treating amyotrophic lateral sclerosis (ALS).
Organizers of the One Brave Idea research funding opportunity recently announced the 10 finalists who have been chosen for the last round of the competition, which gives the winner $75 million for research.
Researchers recently evaluated the brain differences between male and female worms to determine how the sexually dimorphic connections -- those which occur in either males or females -- develop inside the nervous system.
The goal of the Parker Institute for Cancer Immunotherapy is to accelerate the development of cutting-edge immune therapies capable of turning cancer into a curable disease by ensuring the collaboration of the field’s top researchers and quickly converting their findings into patient treatments.